Abstract:Obsessive-compulsive disorder (OCD) is common in schizophrenia patients treated with antipsy-chotics with significant anti-serotoninergic action. Clozapine was the first drug reported and is still the medication more frequently associated with OCD, along with olanzapine. The aim of this study was to study the OCD prevalence, clinical profile and associated severity factors, using electronic records of a large cohort of clozapine-medicated schizophrenic patients. Patients were routinely screened for OCD using standardised scales as well as relevant clinical, psychometric and demographic data. The electronic records of a large cohort of clozapine-medicated schizophrenia patients routinely screened for OCD using standard measures were used. The Obsessive Compulsive Inventory Revised version (OCI-R) was available from 118 cases and a 21 points cut-off threshold for OCD was defined. OCD prevalence was 47% and significantly higher in patients on several medications including clozapine than on clozapine monotherapy (64% vs 31%; p=.001). Two OCI-R factors had significantly higher scores in these patients and were associated with distinct risk factors: checking behaviour (mean=5.1; SD=3.6), which correlated with length on clozapine treatment (r=.21; p=.026), and obsessing factor (mean=4.8; SD=3.6), which correlated with psychosis severity (r=.59; p=.001). However, these factors along with total OCI-R, did not correlate with either clozapine dose or plasma levels, after correcting for psychosis severity. We propose an imbalance between impaired goal-directed behaviour and habit formation in favour of the latter in clozapine-OCD as a potential theoretical framework for our results. Compulsion in clozapine-medicated schizophrenia patients could be understood as a long-term by-product of the psychosis (even after remission) perpetuated by clozapine’s potent antiserotoninergic properties. Screening for OCD in clozapine patients, and probably in those treated with structurally similar drugs like olanzapine, should be widely adopted by clinicians.

2653 – Influence of polymorphisms in genes SLC1A1, GRIN2B and GRIK2 on clozapine-induced obsessive-compulsive symptoms

Influence of Polymorphisms in Genes SLC1A1, GRIN2B, and GRIK2 on Clozapine-Induced Obsessive–compulsive Symptoms

Clinical Characteristics and Association Analysis of Serotonin 2A Receptor Gene T102C Polymorphism with Obsessive Compulsive Symptoms in Three Different Conditions

A Linkage Analysis Between Obsessive Compulsive Spectrum Disorders and Candidate Genes of Group II Metabotropic Glutamate Receptor

[Molecular Pharmacogenetic Studies of Drug Responses to Obsessive-Compulsive Disorder and Six Functional Genes].

COMT, 5-HTR2A, and SLC6A4 Mrna Expressions in First-Episode Antipsychotic-Naïve Schizophrenia and Association with Treatment Outcomes

S92. DISTINCT RISK FACTORS FOR OBSESSIVE AND COMPULSIVE SYMPTOMS IN SCHIZOPHRENIA

Association of SLC1A1 gene polymorphism with obsessive compulsive disorder in a sample from southern India.

Association of rs11081062 polymorphism of DLGAP1 gene and levels of SLC1A1 protein with obsessive-compulsive disorder

Distinct Risk Factors for Obsessive and Compulsive Symptoms in Chronic Schizophrenia.

A Cross Sectional Study of Impact and Clinical Risk Factors of Antipsychotic-Induced OCD

Neurotransmitter system gene variants as biomarkers for the therapeutic efficacy of rTMS and SSRIs in obsessive-compulsive disorder

A study on the association between T102C polymorphism in the 5-HT2a receptor gene and responses to clozapine

Association of Delta Opioid Receptor Gene Polymorphism with Metabolic Syndrome Induced by Clozapine in Schizophrenic Patient

Association Analysis of Serotonin 2A Receptor Gene Polymorphism and Obsessive-Compulsive Disorder

Analysis the Relationship Between Polymorphism in the Serotonin 2A Receptor Gene and Variability among Individuals in Their Response to Clozapine

Lower levels of whole blood serotonin in obsessive-compulsive disorder and in schizophrenia with obsessive-compulsive symptoms.

Study on Clinical Characteristic and Whole-Blood Serotonin Concentration of Obsessive-Compulsive Symptoms in Three Different Conditions

Modulation on Glutamic Pathway of Frontal-Striatum-Thalamus by Rs11146020 and Rs3813296 Gene Polymorphism in First-Episode Negative Schizophrenia

Pharacogenetic Effects of Dopamine Transporter Gene Polymorphisms on Response to Chlorpromazine and Clozapine and on Extrapyramidal Syndrome in Schizophrenia

A novel, putative gain-of-function haplotype at SLC6A4 associates with obsessive-compulsive disorder